** Pfizer PFE.N on Tuesday beat Wall Street estimates for fourth-quarter profit driven by cost cuts and steadier COVID vaccine sales
** PFE has been looking to show investors steadier execution and growth after large swings related to its COVID-19 vaccine
OBESITY DATA IS 'LITMUS TEST' FOR PIPELINE
** BMO Capital Markets ("Outperform", PT: $38) says Pfizer continues to execute the plan outlined for investors in what is shaping up to be a manageable macro and political environment
** J.P Morgan ("Neutral", PT: $30) says that while it sees several assets in PFE's pipeline (particularly in oncology) that could make the story more interesting, further progress is necessary to change the narrative on shares
** Guggenheim Partners ("Buy", PT: $33) says data from Pfizer's experimental obesity drug, danuglipron, will be a "litmus test for the company's pipeline productivity"
** Leerink ("Market Perform," PT: $28) says "management is executing well and delivering results above expectations, but we await future pipeline developments"
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。